Jazz Pharmaceuticals plc - 8-K Filing
FDA approves two new regimens for first-line treatment of HER2+ gastroesophageal adenocarcinoma with Jazz Pharmaceuticals' Ziihera (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $JAZZ